Clinical trial
Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
NCT00170898 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00170898 |
|---|---|
| Title | Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain |
| Official title | A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Acute Musculoskeletal Pain Due to Uncomplicated Soft Tissue Injury |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Musculoskeletal Pain |
| Intervention type | Drug |
| Interventions | Lumiracoxib |
| Enrollment | 419 |
| Start date | Nov 1, 2004 |
| First posted | Sep 15, 2005 |
| Last update posted | Oct 13, 2006 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: